Lineage Cell Therapeutics (LCTX) Q4 2024 earnings summary

Executive summary

• OpRegen, the lead candidate for dry AMD, continues to progress in the Phase IIa GALET Study, with partners Roche and Genentech increasing activity and obtaining RMAT designation from the FDA, supporting ongoing development.

• Achieved positive 24-month and three-year visual acuity data for OpRegen in geographic atrophy patients, with durable anatomical and functional improvements and vision gains persisting versus standard therapies.

• Significant investments in scalable GMP manufacturing and new patents have positioned the company as a leader in allogeneic cell therapy production, aiming for millions of doses per batch.

• OPC1, the spinal cord injury program, is advancing with a new delivery device, improved manufacturing, and the DOSED clinical study, targeting chronic patients for the first time.

• Strengthened balance sheet with $44 million in gross proceeds from two financings, with potential for an additional $36 million upon warrant exercise.

Financial highlights

• Year-end cash, cash equivalents, and marketable securities totaled $47.8 million as of December 31, 2024, with an additional $5.5 million received in January, extending runway into Q1 2027.

• Q4 2024 revenues were $2.9 million, up $0.8 million year-over-year, primarily from increased collaboration revenue from Roche.

• Q4 operating expenses were $7.8 million, down $0.4 million year-over-year; net loss for Q4 was $3.3 million ($0.02/share), improved from $4.8 million ($0.03/share) in Q4 2023.

• Full-year 2024 revenues were $9.5 million, up $0.6 million; operating expenses were $31 million, down $2.7 million; net loss was $18.6 million ($0.09/share), improved from $21.5 million ($0.12/share) in 2023.

• Other income for 2024 was $2.9 million, up from $1.5 million in 2023, mainly due to changes in warrant liability fair value and marketable securities.

Outlook and guidance

• Cash runway supports operations into Q1 2027, with potential for an additional $36 million from milestone warrants if clinical milestones are achieved.

• Awaiting potential decision by Roche/Genentech to advance OpRegen to a controlled trial, which could trigger further funding and program acceleration.

• Anticipates advancing internal programs through key milestones in 2025, including the DOSED clinical study for OPC1 and further development of Resonance.